Pfizer shares offer both opportunity and uncertainty, facing regulatory hurdles and scrutiny although attracting investor interest because of their low price. Per Jim Cramer, the stock is 'dead money', yet analysts persistently query 'Is Pfizer Stock a Buy?', suggesting a conflicted market sentiment. Pfizer is compared against peers like Moderna and Johnson & Johnson, while facing competition from Alnylam in a growing market. Some articles point to Pfizer's stock as a great dividend source, but others pointedly ask if the stock is a good investment or not. With a majority of institutional backing, the company seems to have financial strength, but proxy advisers are against its executive pay proposal. The stock has dipped, performed compared to other pharmaceutical stocks, and run amidst various market complexities. Plunges in partner companies and reports of U.S. probes related to its COVID vaccine's success also cast shadows over the stock's future. Recurring themes of being undervalued and a looming first-quarter slowdown project contrasting future prospects. Recent quarterly revenues exceeded expectations and the 2025 guidance has been reaffirmed, drawing potential positivity around the stock.
Pfizer Stocks News Analytics from Fri, 15 Nov 2024 08:00:00 GMT to Sat, 05 Apr 2025 14:14:53 GMT -
Rating 3
- Innovation 0
- Information 8
- Rumor -5
